Two European telehealth studies, both with congestive heart failure patients presented results that were–how shall we say it–ambivalent about telehealth efficacy. The ‘Telemedicine to Improve Mortality in Heart Failure’ two-year study (TIM-HF) study from Charité Universitätsmedizin, Berlin, used a RPM system that cost €16 million (!) to develop–and found no significant benefits after 26 months of monitoring except for a sub-group with select physiological conditions. In the ‘Tailored Telemonitoring in Patients with Heartfailure’ (TEHAF) study, from Maastricht University Medical Centre (The Netherlands), Bosch’s Health Buddy was used for a CHF group over one year to provide feedback on symptoms, but no vital signs were transmitted save weight. The group with CHF for less than 18 months had significant improvement, but not so for those with a diagnoses more than 18 months old. But visits to nurses were fewer. Ed. Donna wonders how €16 million can be spent to design a CHF monitoring system which can come from a number of providers, and why the Dutch study didn’t use the full capability of Health Buddy. HealthcareITNews Hat tip to Laurie Orlov of Aging in Place Technology.